-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Structure Therapeutics, Maintains $80 Price Target

Benzinga·04/22/2025 10:17:04
Listen to the news
HC Wainwright & Co. analyst Andrew Fein maintains Structure Therapeutics (NASDAQ:GPCR) with a Buy and maintains $80 price target.